The objective of this study was to use EGF mapping to identify different subtypes of persistent AF based on characteristics of the AF sources and to predict post‐ablation outcomes at 12 months based on the AF source subtype and whether or not relevant sources remained at the conclusion of the ablation procedure. The gene discussed is EGF; the disease is atrial fibrillation.